A multicenter phase I/II trial of MFA/TMZ combination therapy in relapsed MGMT‐methylated glioblastoma (MecMeth/NOA‐24 trial, EudraCT2021‐000708‐39) which was initiated upon our previous experimental findings will measure the concentration of MFA within the resected tumor tissue to address this question and will for the first time evaluate the safety and feasibility of a therapeutic approach directed against the tumor network [29, 61]. Here, MGMT is linked to glioblastoma.